Market Overview

According to Fortune Business Insights, the global dry eye treatment devices market size was valued at USD 380.35 million in 2025. The market is projected to grow from USD 409.72 million in 2026 to USD 742.89 million by 2034, exhibiting a CAGR of 7.72% during the forecast period. North America dominated the dry eye treatment devices market with a revenue share of 38% in 2025.

Fortune Business Insights™ has deep-dived into these insights in its latest research report, titled “Dry Eye Treatment Devices Market, 2026-2034.”

The analysis shows that the market is experiencing significant expansion due to the increasing prevalence of dry eye disease (DED), meibomian gland dysfunction (MGD), prolonged digital screen exposure, and a growing aging population. Device-based therapies—such as Meibomian Gland Expression (MGX), Intense Pulsed Light (IPL), thermal pulsation systems, and combination therapies—have gained strong acceptance among ophthalmologists because they offer targeted treatment for underlying causes rather than temporary symptom relief. This trend indicates a strong global demand for non-invasive, efficient, and long-lasting treatment solutions for chronic dry eye conditions.

Major Players Profiled in the Market Report:

• Johnson & Johnson Vision Care
• Alcon, Inc.
• Sight Sciences
• Lumenis
• MiBo Medical Group
• ESW Vision

Segments

Proven Effectiveness in Restoring Tear Film Stability to Propel Meibomian Gland Expression (MGX) Segment Growth

Based on technology, the market is segmented into Meibomian Gland Expression (MGX), Intense Pulsed Light (IPL), thermal pulsation systems, and combination therapy systems. The MGX segment holds the largest market share at approximately 41% and dominates the market owing to its direct therapeutic approach and proven effectiveness in removing gland obstructions and restoring natural lipid secretion. Meanwhile, combination therapy systems integrating MGX and IPL account for approximately 29% of the market share, gaining substantial attention for their ability to reduce inflammation and facilitate physical gland clearance simultaneously.

Hospitals to Dominate the Market Due to Advanced Infrastructure and High Patient Volumes

By end-use, the market is bifurcated into hospitals and ophthalmic clinics. The hospitals segment holds the largest market share at approximately 56% owing to extensive ophthalmology departments, access to multidisciplinary care teams, clinical research programs, and the capacity to treat high volumes of patients with moderate to severe dry eye conditions. Conversely, ophthalmic clinics account for approximately 44% of the market share and represent one of the fastest-growing segments, driven by shorter waiting times, specialized expertise, and the rise of dedicated dry eye centers.

Geographically, the market is studied across North America, Europe, Asia-Pacific, and the Rest of World (including Latin America, the Middle East, and Africa).

For detailed market insights: https://www.fortunebusinessinsights.com/dry-eye-treatment-devices-market-117807

Report Coverage

The report offers: